Alterity Therapeutics Limited
NASDAQ:ATHEBiotechnology
+$0.53 today
- Market cap
- $52.77M
- Beta
- -0.03
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$0.07
Volume 0.02M
Average 0.05M
ATHE Deferred Income Tax
The difference between tax expense recognized and tax actually paid in cash during the period.
Alterity Therapeutics LimitedNASDAQ: ATHE
Deferred Income Tax · Q2 FY2026 · quarter ended Dec 2025
Deferred income tax outflow grows to A$0
Q2 FY2026 deferred income tax was A$0, compared with A$0 a year earlier.
Context
- Deferred income tax amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Deferred income tax increased in 1 of the last 3 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Deferred Income Tax history
AUD · from the cash flow
- Latest · FY2025
- 0 AUD
- Year-over-year change
- —
| Period | Period end | Deferred Income Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 0 | — |
| FY2024 | 2024-06-30 | 0 | -100.0% |
| FY2023 | 2023-06-30 | 2.99M | +382.6% |
| FY2022 | 2022-06-30 | (1.06M) | -145.4% |
| FY2021 | 2021-06-30 | 2.33M | — |
Deferred Income Tax vs competitors
How ATHE compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred income tax is compared through growth and share of revenue rather than absolute size.
- Deferred income tax amounts to 0.0% of revenue for ATHE, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | A$0 AUD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding ATHE) | — | — | — | 0.0% | |
Competitors are the stored peer set for ATHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Net Income | (15.31M) | (12.85M) | (13.81M) | (19.12M) | (12.15M) |
| Depreciation & Amortization | 75.37K | 54.21K | 102.26K | 147.53K | 139.72K |
| Deferred Income Tax | 2.33M | (1.06M) | 2.99M | 0 | 0 |
| Stock-Based Compensation | 1.88M | 1.51M | 966.57K | 881.95K | 979.92K |
| Change in Working Capital | (4.22M) | (447.68K) | (3.94M) | 5.75M | (613.68K) |
| Accounts Receivables | (4.22M) | (447.68K) | (3.94M) | 4.62M | 104.07K |
| Inventory | 191.13K | (2.21M) | 2.45M | 0 | 0 |
| Accounts Payables | 432.91K | 2.6M | (1.56M) | 1.1M | 0 |
| Other Working Capital | (624.03K) | (393.29K) | (889.52K) | 23.05K | (717.75K) |
| Other Non-Cash Items | (2.1M) | 455.57K | (6.35M) | (261.15K) | 190.62K |
| Operating Cash Flow | (17.33M) | (12.34M) | (20.04M) | (12.61M) | (11.45M) |
| Capital Expenditures | (10.47K) | (89.15K) | (7.31K) | (5.72K) | 3 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (7.5M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (29.15K) | 0 | 0 |
| Investing Cash Flow | (10.47K) | (89.15K) | (36.46K) | (5.72K) | (7.5M) |
| Debt Repayment | (58.29K) | (34.51K) | (59.92K) | (10.37K) | (127.1K) |
| Common Stock Issued | 39.24M | 17.18M | 316.68K | 10.14M | 42.57M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.49M) | (836.97K) | (132.41K) | (918.02K) | (2.77M) |
| Financing Cash Flow | 36.69M | 16.3M | 124.34K | 9.22M | 39.67M |
| Effect of Forex Changes | (426.78K) | 2.81M | 914.94K | 260.36K | (198.38K) |
| Net Change in Cash | 18.92M | 6.69M | (19.03M) | (3.13M) | 20.52M |
| Free Cash Flow | (17.34M) | (12.43M) | (20.04M) | (12.61M) | (11.45M) |
Alterity Therapeutics Limited
NASDAQ:ATHE
Intrinsic Alpha fair value
Locked
Current Price
$3.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.